

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/521,707
Filing Date	19 January 2005
First Named Inventor	Janice A. JERDAN et al.
Art Unit	
Examiner Name	
Attorney Docket Number	2422 US F

Sheet 1 of 2

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 4,876,250	10/24/1989	Clark	
		US- 5,371,078	12/06/1994	Clark et al.	
		US- 5,679,666	10/21/1997	Clark	
		US- 5,698,545	12/16/1997	Clark et al.	
		US- 5,770,592	06/23/1998	Clark	
		US- 6,413,540	07/02/2002	Yaacobi	
		US- 6,416,777	07/09/2002	Yaacobi	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	1*
		Country Code ² Number ³ Kind Code ⁴ (if known)	MM-DD-YYYY			
		EP 1 039 912 B1	08/07/2002	Alcon Labs		
		WO 00/02127 A1	07/01/2000	Alcon Labs		
		WO 02/00784 A1	02/06/2002	Yaacobi		
		WO 00/009774 A2	02/06/2000	Yaacobi		

Examiner Signature	/Joseph Kudla/	Date Considered	06/04/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Copyright Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Approved for use through 07/31/2006. OMB 0851-0031

Complete if Known

Substitute for form 1449		Application Number		10/521,707	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date		19 January 2005	
		First Named Inventor		Janice A. JERDAN et al.	
		Art Unit			
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	2422 US F

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	BENEZRA, et al., Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization, Invest. Ophthalmol. Vis. Science, 1997, Vol. 38:1954-62	
	B2	CASEY, et al., Factors Controlling Ocular Angiogenesis, Amer. J. Ophthalmol., 1997, Vol. 124: 521-529	
	B3	CLARK, A.F., AL-3789: a novel ophthalmic angiostatic steroid, Exp. Opin. Invest. Drugs, 1997, Vol. 6:1867-77	
	B4	DEFALLER, et al., A new pharmacological treatment for angiogenesis. In Pterygium, Taylor, HR (ED.) The Hague: Kugler Publications, 2000, 159-181	
	B5	KRZYSTOLIK, et al., Preclinical & Phase 1A Clinical Evaluation of an Anti-VEGF pegylated aptamer (EYE001) for the treatment... Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor..., Arch. Ophthalmol., 2002, Vol. 120:338-46	
	B6	MCNATT, et al., Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization, J. Ocular Pharm. Therap., 1999, Vol. 15(5):413-23	
	B7	PENN, et al., The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity, Invest. Ophthalmol. Vis. Science, 2001, Vol. 42:283-90	
	B8	Photodynamic therapy of subfoveal..., Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, Arch. Ophthalmol., 1999, Vol. 117:1329-45	
	B9	Preclinical and Phase 1A Clinical Evaluation of an Anti-VEGF pegylated aptamer (EYE001) for the treatment..., The EyeTech Study Group, Retina, 2002, Vol. 22:143-52	

Examiner Signature	/Joseph Kudla/	Date Considered	06/04/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //J.K./